Invus Public Equities, L.p. - Net Worth and Insider Trading

Invus Public Equities, L.p. Net Worth

The estimated net worth of Invus Public Equities, L.p. is at least $258 Million dollars as of 2024-04-28. Invus Public Equities, L.p. is the 10% Owner of Scholar Rock Holding Corp and owns about 11,259,438 shares of Scholar Rock Holding Corp (SRRK) stock worth over $164 Million. Invus Public Equities, L.p. is the Director, 10% Owner of Lexicon Pharmaceuticals Inc and owns about 35,402,689 shares of Lexicon Pharmaceuticals Inc (LXRX) stock worth over $56 Million. Invus Public Equities, L.p. is also the 10% Owner of GlycoMimetics Inc and owns about 8,589,064 shares of GlycoMimetics Inc (GLYC) stock worth over $14 Million. Besides these, Invus Public Equities, L.p. also holds Seer Inc (SEER) , Generation Bio Co (GBIO) , Omega Therapeutics Inc (OMGA) , Agenus Inc (AGEN) , SQZ Biotechnologies Co (SQZB) . Details can be seen in Invus Public Equities, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Invus Public Equities, L.p. has not made any transactions after 2023-10-12 and currently still holds the listed stock(s).

Transaction Summary of Invus Public Equities, L.p.

To

Invus Public Equities, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Invus Public Equities, L.p. owns 8 companies in total, including Generation Bio Co (GBIO) , Lexicon Pharmaceuticals Inc (LXRX) , and Scholar Rock Holding Corp (SRRK) among others .

Click here to see the complete history of Invus Public Equities, L.p.’s form 4 insider trades.

Insider Ownership Summary of Invus Public Equities, L.p.

Ticker Comapny Transaction Date Type of Owner
GBIO Generation Bio Co 2020-06-16 10 percent owner
LXRX Lexicon Pharmaceuticals Inc 2020-12-16 director & 10 percent owner
SRRK Scholar Rock Holding Corp 2023-10-12 10 percent owner
AGEN Agenus Inc 2008-05-10 10 percent owner
SQZB SQZ Biotechnologies Co 2020-11-03 10 percent owner
SEER Seer Inc 2021-02-01 10 percent owner
OMGA Omega Therapeutics Inc 2021-08-03 10 percent owner
GLYC GlycoMimetics Inc 2023-02-24 10 percent owner

Invus Public Equities, L.p. Latest Holdings Summary

Invus Public Equities, L.p. currently owns a total of 8 stocks. Among these stocks, Invus Public Equities, L.p. owns 11,259,438 shares of Scholar Rock Holding Corp (SRRK) as of October 12, 2023, with a value of $164 Million and a weighting of 63.42%. Invus Public Equities, L.p. owns 35,402,689 shares of Lexicon Pharmaceuticals Inc (LXRX) as of December 16, 2020, with a value of $56 Million and a weighting of 21.68%. Invus Public Equities, L.p. also owns 8,589,064 shares of GlycoMimetics Inc (GLYC) as of February 24, 2023, with a value of $14 Million and a weighting of 5.46%. The other 5 stocks Seer Inc (SEER) , Generation Bio Co (GBIO) , Omega Therapeutics Inc (OMGA) , Agenus Inc (AGEN) , SQZ Biotechnologies Co (SQZB) have a combined weighting of 9.44% among all his current holdings.

Latest Holdings of Invus Public Equities, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SRRK Scholar Rock Holding Corp 2023-10-12 11,259,438 14.53 163,599,634
LXRX Lexicon Pharmaceuticals Inc 2020-12-16 35,402,689 1.58 55,936,249
GLYC GlycoMimetics Inc 2023-02-24 8,589,064 1.64 14,086,065
SEER Seer Inc 2021-02-01 5,588,366 1.91 10,673,779
GBIO Generation Bio Co 2020-06-16 2,814,191 2.90 8,161,154
OMGA Omega Therapeutics Inc 2021-08-03 2,273,530 2.27 5,160,913
AGEN Agenus Inc 2008-05-10 29,444 11.69 344,200
SQZB SQZ Biotechnologies Co 2020-11-03 160,631 0.05 7,469

Holding Weightings of Invus Public Equities, L.p.


Invus Public Equities, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Invus Public Equities, L.p. has made a total of 6 transactions in Scholar Rock Holding Corp (SRRK) over the past 5 years, including 5 buys and 1 sells. The most-recent trade in Scholar Rock Holding Corp is the acquisition of 2,199,931 shares on October 12, 2023, which cost Invus Public Equities, L.p. around $15 Million.

According to the SEC Form 4 filings, Invus Public Equities, L.p. has made a total of 1 transactions in Lexicon Pharmaceuticals Inc (LXRX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Lexicon Pharmaceuticals Inc is the acquisition of 10,937,500 shares on December 16, 2020, which cost Invus Public Equities, L.p. around $35 Million.

According to the SEC Form 4 filings, Invus Public Equities, L.p. has made a total of 4 transactions in GlycoMimetics Inc (GLYC) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in GlycoMimetics Inc is the acquisition of 100,000 shares on February 24, 2023, which cost Invus Public Equities, L.p. around $170,000.

More details on Invus Public Equities, L.p.'s insider transactions can be found in the Insider Trading History of Invus Public Equities, L.p. table.

Insider Trading History of Invus Public Equities, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Invus Public Equities, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Invus Public Equities, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Invus Public Equities, L.p. is 10.88%. GuruFocus also compares Invus Public Equities, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Invus Public Equities, L.p. within 3 months outperforms 11 times out of 24 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Invus Public Equities, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Invus Public Equities, L.p.

Average Return

-11.58%

Average return per transaction

Outperforming Transactions

36%

8 out of 22 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 7.45 10.88 -12.44 -11.58 -53.37 -37.44
Relative Return to S&P 500(%) 5.71 5.21 -17.26 -25.96 -59.2 -50.62

Invus Public Equities, L.p. Ownership Network

Ownership Network List of Invus Public Equities, L.p.

No Data

Ownership Network Relation of Invus Public Equities, L.p.


Invus Public Equities, L.p. Owned Company Details

What does Generation Bio Co do?

Who are the key executives at Generation Bio Co?

Invus Public Equities, L.p. is the 10 percent owner of Generation Bio Co. Other key executives at Generation Bio Co include CHIEF OPERATING OFFICER Antoinette Paone , CHIEF LEGAL OFFICER Yalonda Howze , and CHIEF STRATEGY OFFICER Phillip Samayoa .

Generation Bio Co (GBIO) Insider Trades Summary

Over the past 18 months, Invus Public Equities, L.p. made no insider transaction in Generation Bio Co (GBIO). Other recent insider transactions involving Generation Bio Co (GBIO) include a net sale of 10,590 shares made by Antoinette Paone , a net purchase of 20,000 shares made by Dannielle Appelhans , and a net purchase of 342,960 shares made by Rowland Charles A Jr .

In summary, during the past 3 months, insiders sold 0 shares of Generation Bio Co (GBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 12,455 shares of Generation Bio Co (GBIO) were sold and 551,455 shares were bought by its insiders, resulting in a net purchase of 539,000 shares.

Generation Bio Co (GBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Generation Bio Co Insider Transactions

No Available Data

Invus Public Equities, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Invus Public Equities, L.p.. You might contact Invus Public Equities, L.p. via mailing address: C/o The Invus Group, Llc, 750 Lexington Avenue, 30th Floor, New York Ny 10022.

Discussions on Invus Public Equities, L.p.

No discussions yet.